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It has been suggested that the restricted, stereotyped and repetitive behaviours typically found in autism are underpinned by
deficits of inhibitory control. The biological basis of this is unknown but may include differences in the modulatory role of
neurotransmitters, such as serotonin, which are implicated in the condition. However, this has never been tested directly.
We therefore assessed the modifying role of serotonin on inhibitory brain function during a Go/No-Go task in 14 adults
with autism and normal intelligence and 14 control subjects that did not differ in gender, age and intelligence. We undertook
a double-blind, placebo-controlled, crossover trial of acute tryptophan depletion using functional magnetic resonance imaging.
Following sham, adults with autism relative to controls had reduced activation in key inhibitory regions of inferior frontal cortex
and thalamus, but increased activation of caudate and cerebellum. However, brain activation was modulated in opposite ways
by depletion in each group. Within autistic individuals depletion upregulated fronto-thalamic activations and downregulated
striato-cerebellar activations toward control sham levels, completely ‘normalizing’ the fronto-cerebellar dysfunctions.
The opposite pattern occurred in controls. Moreover, the severity of autism was related to the degree of differential modulation
by depletion within frontal, striatal and thalamic regions. Our findings demonstrate that individuals with autism have abnor-
mal inhibitory networks, and that serotonin has a differential, opposite, effect on them in adults with and without autism.
Together these factors may partially explain the severity of autistic behaviours and/or provide a novel (tractable) treatment
target.
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Introduction
Autism spectrum disorder (ASD) is a highly genetic neurodevelop-
mental condition affecting 41% of the population (Autism and
Developmental Disabilities Monitoring Network Surveillance Year,
2008 Principal Investigators, 2012). A core diagnostic feature of
ASD is restricted, stereotyped and repetitive behaviours (RSRB)
(WHO, 1992). There is substantial indirect evidence that these
symptoms are underpinned by deficits in executive function and
in particular inhibitory control (Hill, 2004).
The neuroanatomical systems proposed to be involved in the
RSRB typically found in ASD include the inferior frontal and
cingulate cortices, thalamus, and basal ganglia (McAlonan et al.,
2002; Langen et al., 2012). These are also the key areas mediating
motor response inhibition in the ‘neurotypical’ population
(Chambers et al., 2009). Functional MRI studies of healthy
adults have investigated brain activation during inhibitory control
(using a Go/No-Go task) and have reported that the right frontal
gyrus, left thalamus, and right cerebellum are associated with the
inhibitory No-Go response (Liddle et al., 2001). Additionally, Go/
No-Go and functional MRI studies of adults with ASD describe
functional abnormalities within inhibition areas including greater
activation in the left inferior frontal gyrus (Schmitz et al., 2006)
and less activation in the right inferior frontal gyrus when
compared with control subjects (Schmitz et al., 2006; Kana
et al., 2007).
The biological basis for these differences is unknown, but may
include modulatory effects of serotonin (5-hydroxytryptophan,
5-HT). In healthy populations, there is evidence that serotonin is
involved in motor inhibition (Soubrié, 1986; Lucki, 1998; Robbins
and Crockett, 2010) by suppressing behavioural responses. Studies
combining functional MRI and the modulation of serotonin levels
in healthy controls report brain activation changes in frontal cortex
and striatum when performing the Go/No-Go inhibition task
(Anderson et al., 2002; Del-Ben et al., 2005; Rubia et al., 2005;
Vollm et al., 2006; Lamar et al., 2009).
When compared to ‘neurotypicals’, there is consistent evi-
dence that individuals with ASD have abnormalities in the seroto-
nergic system including physiology, neurobiology and genetics
(Cook and Leventhal, 1996; Zafeiriou et al., 2009). For example,
research indicates that a significant proportion of subjects with ASD
may have hyperserotonaemia (Hranilovic et al., 2009). As well as
detecting increased blood levels of serotonin in first-degree relatives
of subjects with ASD (Piven et al., 1991; Leboyer et al., 1999),
hyperserotonaemic parents of ASD subjects are reported to have
higher ratings of repetitive behaviours (Cook et al., 1994).
Additionally, the severity of repetitive behaviours in subjects with
ASD are related to the sensitivity of the serotonin-1d receptor, as
measured by growth hormone response to receptor agonist suma-
triptan (Hollander et al., 2000)
In addition to neuroanatomical differences (McAlonan et al.,
2002; Langen et al., 2011), there are preliminary functional neu-
roimaging reports that individuals with ASD have significant dif-
ferences from control subjects in serotonin synthesis (Chugani
et al., 1997); as well as reductions in serotonin-2A receptor and
serotonin transporter binding in brain regions (including inferior
prefrontal cortex) that mediate executive and inhibitory function-
ing (Murphy et al., 2006; Nakamura et al., 2010). There are also
reports of significant associations between ASD and genetic poly-
morphisms for serotonin synthesis, transporters and receptors
(Devlin et al., 2005; Anderson et al., 2009).
Brain levels of serotonin are dependent on the blood concen-
tration of its chemical precursor tryptophan, which is in direct
competition with other neutral amino acids, large and small, to
cross the blood–brain barrier (Fernstrom, 1983). People with ASD
have a significantly lower ratio of tryptophan to other amino acids
compared to control subjects (D’Eufemia et al., 1995). There is,
therefore, increasing indirect evidence that some abnormalities in
brain function within ASD may be underpinned by serotonin
abnormalities. This issue can be addressed using acute tryptophan
depletion (ATD)—a non-invasive technique for reducing serotonin
levels in the brain (Young et al., 1989; Young, 2013). Blood levels
of tryptophan, and subsequently brain serotonin, are decreased by
the consumption of an amino acid mixture lacking tryptophan as
compared to their increase by consumption of a sham mixture
containing tryptophan. In ‘neurotypicals’, pharmacological func-
tional MRI studies of action restraint inhibition tasks using ATD
have reported that serotonin reduces neural activation of inferior
frontal and striatal inhibitory control regions and increases activa-
tion of cerebellum, temporal and parietal lobes (Rubia et al., 2005;
Lamar et al., 2009). Also, we have previously reported that in
ASD, tryptophan depletion differentially modulates brain activation
during facial emotion processing (Daly et al., 2012).
However, to our knowledge, no one has investigated the mod-
ulatory effect of serotonin on inhibitory neural activity in individ-
uals with ASD. Also nobody has related clinical severity of RSRB
symptoms to differences in brain response to serotonin. Hence,
the aim of this functional MRI study was to investigate the modu-
lation of blood oxygen level-dependent (BOLD) response by ATD
during performance of a Go/No-Go task in adults with and with-
out ASD.
We hypothesized that in the non-ATD condition there would be
significant group differences in activation of classical inhibitory
control regions such that subjects with ASD compared to controls
would show decreased activation in right inferior frontal and
increased activation in left inferior frontal cortices (Schmitz
et al., 2006; Kana et al., 2007). These differences would be
modulated by serotonin reduction whereas the control subjects
would show decreased right inferior frontal cortex and striatial
activations (Rubia et al., 2005; Lamar et al., 2009). We further
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hypothesized that within the subjects with ASD, abnormal activa-
tion and differential serotonin modulation would both be related
to severity of RSRB.
Materials and methods
Subjects
We recruited 14 right-handed adult males with autism through a clin-
ical research programme at the Maudsley Hospital/King’s College
London’s Institute of Psychiatry (London). An autism diagnosis was
based on application of ICD-10 research criteria (WHO, 1993), and
confirmed using the Autism Diagnostic Interview-Revised (ADI-R)
(Lord et al., 1994). Subjects reached ADI-R algorithm cut-offs in the
three domains of impaired reciprocal social interaction, communication
and repetitive behaviours and stereotyped patterns, although failure to
reach cut-off in one of the domains by 1 point was permitted. Current
symptoms were assessed using the Autism Diagnostic Observational
Schedule (ADOS) (Lord et al., 1989). We were unable to obtain the
interview for two of the subjects whose diagnoses were confirmed
using the observational schedule (Table 1).
We also included 14 healthy, right-handed, adult male control sub-
jects recruited locally by advertisement. They did not differ significantly
from the males with autism in age (mean years: ASD = 31  13; con-
trols = 31  11; t-test P = 0.9) or overall intelligence as measured by
the Wechsler Adult Intelligence Scale (Wechsler, 1981) (mean full
scale: ASD = 115  13; controls = 123  20; t-test P = 0.2) (Table 1).
All subjects had routine clinical and genetic screening blood tests to
ensure good medical health and a structured clinical exam to exclude
psychiatric illness (e.g. schizophrenia, major depression), head injury,
genetic disorder associated with autism (e.g. fragile X syndrome, tu-
berous sclerosis), and neurological or medical disorders that might
affect brain function (e.g. epilepsy or hypertension). None of the par-
ticipants were abusing alcohol, taking any illicit drugs and none were
prescribed antipsychotic medication, antidepressants, mood stabilizers
or benzodiazepines. After receiving a description of the study all sub-
jects gave written, informed consent. This study was approved by the
Ethical Committee of the South London and Maudsley NHS
Foundation Trust and the Institute of Psychiatry, King’s College
London.
Depletion/sham procedure by acute
tryptophan depletion
Subjects were tested on two separate occasions separated by 1 week
(range: 0.6–3 weeks). After fasting from midnight, at 8:30 am (5 h
before scanning), subjects drank a 100-g mixture that contained 15
amino acids but lacked aspartic and glutamic acid, to avoid possible
toxicity (Young et al., 1989); and either contained 2.3 g of tryptophan
for the sham (placebo) condition, or no tryptophan for the ATD con-
dition. In a double-blind, counterbalanced, crossover design, subjects
were assigned to order of drink consumption (i.e. within each group,
half received sham first and half received ATD first). The amino acid
recipe with or without tryptophan, included: L-alanine 5.5 g, L-arginine
4.9 g, L-cysteine 2.7 g, glycine 3.2 g, L-histidine 3.2 g, L-isoleucine
8.0 g, L-leucine 13.5 g, L-lysine monohydrochloride 8.9 g, L-methio-
nine 3.0 g, L-phenylalanine 5.7 g, L-proline 12.2 g, L-serine 6.9 g, L-
threonine 6.5 g, L-tyrosine 6.9 g and L-valine 8.9 g. The powder was
mixed with cold water and a flavour of the participant’s choice, and
then drunk over 10 min. See Young (2013) for an overview of the
theory, practice and ethics of ATD method.
Monitoring of affective state and blood
chemistry
Before the study, participants completed baseline self-assessment
measurements of depression (Beck Depression Inventory; Beck and
Steer, 1993), anxiety (Beck Anxiety Inventory; Beck et al., 1988)
and autistic traits [Autism-Spectrum Quotient (Baron-Cohen et al.,
2001) and Obsessive-Compulsive Inventory-Revised (Foa et al.,
2002)].
Table 1 Demographics and plasma tryptophan levels
Control (n = 14) Autism (n = 14)
Characteristics Mean SD Mean SD t-Test P ANOVA P
Age, years 31 11 31 13 0.9
Full-scale IQ 123 20 115 13 0.2
Autism Quotient 12 5 31 9 0.001
OCI-R 10 10 25 15 0.005
BDI 3 4 10 7 0.003
BAI 3 3 11 13 0.04
Autism Diagnostic Inventory-Revised (n = 12)
Reciprocal Social Interaction 17 11
Communication 11 4
RSRB 5 2
Plasma tryptophan mmol/l (n = 14) (n = 14)
SHAM Pre 71 10 78 13 0.1
SHAM Post 140 54 190 77 0.08 0.005
ATD Pre 75 13 76 5 0.9
ATD Post 20 12 23 9 0.5 0.005
OCI-R = Obsessive-Compulsion Inventory-Revised; BDI = Becks Depression Inventory; BAI = Becks Anxiety Inventroy; SHAM = balanced amino acid drink;
Pre = pre-drink; Post = 4.5 h after drink.
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Before consuming the amino acid mixture, a blood sample was
taken to measure tryptophan levels. A second blood sample was
taken immediately before scanning, typically 4.5 h after ingestion.
This time frame is considered to be optimal for capitalizing on the
effects of ATD on behavioural measures and plasma and brain 5-HT
synthesis (Young et al., 1989). Total plasma tryptophan levels were
determined from each blood sample using previously described meth-
ods (Keating et al., 1993).
Self-report visual analogue scale questionnaires administered before
(baseline) and 4.5 h after (follow-up) amino acid drink ingestion mea-
sured various aspects of mood, aggression, and physical symptoms
thought to be associated with ATD including nausea, dizziness, irrit-
ability and anxiety (Supplementary material).
Functional MRI
Activation paradigm: Go/No-Go task
Five hours after ingestion of the amino acid drink, each subject parti-
cipated in the 6-min functional MRI event-related Go/No-Go task
(Rubia et al., 2005). Before the functional MRI, the task was explained
to and practiced by subjects on a laptop outside of the scanner. Within
the scanner, the task was projected onto a screen and viewed by
subjects through a prism mirror attached to the headcoil cage.
Frequent arrows (160 trials: 76%, 500 ms duration) pointing to
either the left or right (Go signals) appeared in the middle of the
screen with a mean intertrial interval of 1.8 s (jittered 1.6–2s).
Infrequently, arrows point up (24 trials, 12%, No-Go signals) or
slightly slanted (by 22.5%) arrows (24 trials, 12%, oddball signals)
appeared. A button response had to be selectively executed with the
right thumb to Go or oddball stimuli or inhibited to No-Go signals. The
oddball trials control for the low frequency of the No-Go trials and
thus the oddball attentional capture effect (Rubia et al., 2005; Schmitz
et al., 2006; Lamar et al., 2009).
A mixed between-within subjects ANOVA was performed in SPSS to
examine the probability differences of inhibition and mean response to
oddball Go trials.
Acquisition
Magnetic resonance images were acquired on a GE Signa 1.5 T
Horizon LX system (General Electric) at the Maudsley Hospital,
London, UK. A quadrature birdcage headcoil was used for radiofre-
quency transmission and reception. An inversion recovery echoplanar
imaging (EPI) data set was acquired at 43 near-axial 3-mm thick slices
parallel to the AC-PC line: echo time = 40 ms, repetition time = 16 s,
in-plane voxel size = 1.875 mm, interslice gap = 0.3 mm, and matrix
size = 128  128 voxel. This higher resolution EPI data set provided
whole brain coverage and was later used to normalize the functional
MRI data sets acquired from each individual in standard stereotactic
space. Functional MRI acquisition consisted of 208 T2*-weighted
images acquired at each of 16 near-axial non-contiguous 7-mm
thick planes parallel to the intercommissural (AC-PC) line: echo
time = 40 ms, repetition time = 1.8 s, in-plane voxel size = 3.75 mm,
interslice gap 0.7 mm, and matrix size = 64  64 voxels.
Data analysis
All functional MRI data were analysed with the XBAM (version 4)
software developed at the Institute of Psychiatry, London, using a
non-parametric approach (www.brainmap.co.uk) as described previ-
ously (Daly et al., 2012) and in the Supplementary material. A brief
overview is given below.
Within each run, every volume was realigned to the mean of all the
images in the run and then smoothed using a Gaussian filter (full-
width at half-maximum 8.8 mm). Using a wavelet-based resampling
method for functional MRI data, a time series analysis was performed
on each individual subject, in order to compute a sum of squares ratio
reflecting the BOLD effect. These individual maps were normalized
into standard Talairach space using affine transformations. Group
brain activation maps were computed for each experimental condition
with hypothesis testing performed at both the voxel and the cluster
level giving excellent type I error control. Using data-driven, permu-
tation-based methods, with minimal distributional assumptions, we
performed time series analyses for group maps and inter-group
random permutation for within/between-group ANOVAs to compute
the distribution of the sum of squares ratio under the relevant null
distribution hypothesis. Thresholding to the required level of signifi-
cance was then performed using a two-stage process: first at a voxel-
wise P-value of 0.05, followed by grouping the supra-threshold voxels
into 3D clusters and testing their significance against a null distribution
of clusters occurring by chance in the permuted data. The cluster-level
threshold was set in such a way as to obtain less than one false posi-
tive cluster per map. Therefore, a corrected threshold is used to min-
imize type 1 errors.
Analysis of variance and correlations
The event-related analyses contrasted the activations (sum of squares
ratio) related to successful No-Go trials compared to successful oddball
trials, controlling for the attentional oddball effect due to the low
frequency occurrence of No-Go trials.
Analysis of variance testing for BOLD response
interactions between tryptophan status and group
membership
For the task, a two-group (between condition: control, autism)  two
tryptophan status (within group: sham, depletion) factorial repeated-
measures ANOVA was undertaken. Group  tryptophan status inter-
actions refer to brain regions in which the effect on the BOLD
response to the No-Go/oddball is different in each group depending
on the status of with and without tryptophan. From each interaction
cluster, for post hoc testing, each subject’s mean BOLD signal
responses (sum of squares) were extracted.
Analysis of variance for BOLD response pair-wise
In the regions showing an interaction effect, main effect of group
analyses were conducted for both the sham and depletion conditions.
Also, a separate main effect of condition analysis was done for both
the control and autism groups.
Analysis of variance testing for BOLD response
‘normalization’ by tryptophan depletion
To test whether brain activations that (i) differed between subjects
with autism and controls; and (ii) showed an interaction between
group  tryptophan status, were normalized after tryptophan deple-
tion, we compared the between-group ANOVA between control sub-
jects and the autism group following sham to the between-group
ANOVA between control subjects at sham and autism group after
tryptophan depletion.
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Correlations between autism restricted, stereotyped and
repetitive, and behaviours and functional MRI BOLD
response of No-Go versus oddball contrast
For the autism group only, Pearson’s product moment correlation
analyses were performed in XBAM to examine any associations
between the severities of RSRBs (as measured by the relevant sub-
scales of the ADI-R and ADOS) and the sum of squares ratios for the
No-Go versus oddball contrast. This was done separately for the sham
and ATD conditions, respectively. For each cluster showing a correl-
ation, the sum of squares ratio was extracted and plotted versus RSRBs
severity in SPSS. Additionally, within the autism group only, we
extracted the sum of squares ratios from the group by drink interaction
analysis to calculate an activation difference between ATD minus sham
condition for each subject. Using SPSS, we calculated a Pearson’s
product moment correlational analyses between these activation
differences and the RSRBs severity scores. We employed a False
Discovery Rate analysis to correct for multiple comparisons.
Results
Baseline measures
Control subjects scored within the normal range on all meas-
ures taken at baseline (Autism-Spectrum Quotient, Obsessive-
Compulsive Inventory-Revised) and pre-drink (Beck Depression
Inventory and Beck Anxiety Inventory). Subjects with autism
scored significantly higher on all four measures compared to con-
trol subjects (for all t-tests P50.04) (Table 1).
Tryptophan blood levels
There were no significant differences in total plasma tryptophan
concentration across groups on either day at baseline. After 4.5 h,
consumption of the sham drink led to a significant increase of total
plasma tryptophan concentrations, in both the controls and
subjects with autism. Following the depletion drink, the total
plasma tryptophan concentrations were significantly reduced
in both groups (Table 1). As expected, in each group, there
was a significant interaction between tryptophan status (sham
versus depletion) and time (baseline versus 4.5 h) [controls:
Wilks’ lambda = 0.04, F(3,11) = 80, P50.0005; autism: Wilk’s
lambda = 0.03, F(3,11) = 140, P50.0005].
Affective measures
Despite between-group differences in baseline measures of
depressive and anxiety symptomatology (Table 1), there were no
significant between-group differences in subjective reports of ad-
verse effects, including nausea and vomiting or for the affective
visual analogue scale measures caused by consumption of the
amino acid drink (Supplementary Table 1).
Functional MRI task response and
movement measures
There were no group  drink differences in the x, y, or z
movement parameters and none of the subjects exceeded
maximum displacement 41 mm. There were no significant be-
tween-group or within-group differences, or interactions of
group by tryptophan status, for the probability of inhibition or
mean reaction time to the No-Go or oddball stimuli
(Supplementary Table 2).
Functional MRI group brain activation
mapping
Group brain activations for the contrast of No-Go-oddball trials for
each of the two drink conditions in both groups revealed acti-
vations in key inhibitory areas such as inferior frontal cortex,
medial frontal gyri, supplementary motor area, striatal and thal-
amic regions at cluster threshold of P50.008 (Fig. 1A–D and
Supplementary Table 3).
Analysis of variance brain activation
mapping
Significant interaction effects of BOLD signal response between
tryptophan drink status (sham, depletion) and group membership
(control, autism) were observed in four (predominately right hemi-
spheric) clusters. These included, the right inferior frontal (reaching
into dorsolateral prefrontal cortex; P50.01), caudate (P50.04)
cerebellum (P50.01) and left thalamus (extending from the
insula to the subthalamic nuclei and to middle temporal gyrus;
P50.001). There were no effects of drink order on any BOLD
responses (Fig. 2A and Table 2).
Main effect of group ANOVAs revealed that after sham,
subjects with autism relative to control subjects, showed reduced
activation in right inferior frontal cortex (P50.003) and left
thalamus (P50.02), but enhanced activation in right cerebellum
(P5 0.003) and caudate (P5 0.007). After depletion, subjects
with autism relative to controls showed enhanced activation
in right inferior frontal cortex (P50.03) and left thalamus
(P5 0.006), but reduced activation in right cerebellum (P50.02)
and caudate (P5 0.02) (Fig. 2B and Table 2).
Main effect of tryptophan status revealed that the BOLD signal
response for controls was decreased due to depletion in the right
inferior frontal cortex (P50.002) and caudate (P50.001). For
the autism group, depletion lead to an increased BOLD signal in
the right inferior frontal cortex (P50.002) and left thalamus
(P5 0.004) and decrease in the right caudate (P50.2) and cere-
bellum (P50.04). The decrease in right caudate did not reach
statistical significance (Fig. 2B and Table 2).
Test for ‘normalization’ by acute
tryptophan depletion of abnormally
activated areas in the autism group
relative to controls
The contrast at sham for controls as compared to depletion for
autism showed absence of any group differences (Fig. 3B).
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Correlations (Pearson’s) between
autism restricted, stereotyped and
repetitive behaviours and functional
MRI BOLD response to No-Go versus
oddball contrast
Subjects with the more severe RSRB symptoms (both past and
present) had the most abnormal brain response (compared to
the controls) and the most pronounced changes (relative to
sham) in some of the inhibition areas indicated by our interaction
analysis. For example, inhibitory BOLD response from the No-Go
versus oddball contrast, under sham conditions, was negatively
correlated with RSRB severity as measured by the ADI-R and
ADOS in the right inferior frontal cortex (n = 12, r = 0.8,
P5 0.006; n = 14, r = 0.7, P5 0.009, respectively) and left
thalamus (n = 12, r = 0.7, P50.008; n = 14, r = 0.7,
P5 0.008, respectively). The BOLD response under depletion
was positively correlated with ADI-R in the right caudate
(n = 12, r = 0.6, P50.05). Additionally, the magnitude of
change in BOLD response between sham and depletion positively
correlated with ADI-R in right caudate (n = 12, r = 0.7, P5 0.02)
and ADOS in left thalamus (n = 14, r = 0.6, P50.02) (Fig. 4).
Discussion
To our knowledge, this is the first event-related functional MRI
study in people with autism to examine the differential effect of
serotonergic modulation (by ATD) on neural activation during a
motor inhibition (Go/No-Go) task; and to relate differences in
functional modulation to clinical symptoms (i.e. RSRBs). Adults
with autism had abnormal activation in classical inhibition areas
(Chambers et al., 2009) of inferior frontal cortex, basal
ganglia, thalamus and cerebellum; in frontal cortex, caudate and
thalamus this was correlated to the severity of RSRB. Depletion
differentially modulated these activations in ‘neurotypicals’ and
in our autism subjects. As previously reported in healthy control
studies, our data are in line with depletion significantly downre-
gulating right inferior frontal cortex and upregulating right cere-
bellum (Rubia et al., 2005; Lamar et al., 2009). By use of the
‘regulation’ terms, we refer to upregulation as an enhanced
BOLD signal for the NoGo versus oddball contrast and con-
versely, downregulation refers to a reduced BOLD signal for the
NoGo versus oddball contrast. Furthermore, the interaction
analysis indicated that in control subjects, tryptophan depletion
downregulated activations in inferior frontal cortex and thal-
amus but upregulated activation in these regions in the autism
Figure 1 Group brain activation maps. Locations of group-wise BOLD signals from NoGo versus oddball contrasts ANOVAs for
(A) controls under sham condition. (B) Controls under depletion condition. (C) ASDs under sham condition. (D) ASDs under depletion
condition. Red = No-Go4oddball. Blue = No-Go5 oddball. Numeric label = z Talairach coordinate. Right hemisphere of brain is on the
right side of the image. CON = controls.
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group. In contrast, depletion downregulated abnormally enhanced
activations in basal ganglia and cerebellum in the autism group
while it upregulated them in controls. Furthermore, the differential
serotonin modulation effects in basal striatal and thalamic activa-
tions were correlated with severity of RSRB in subjects with
autism. For the striatal caudate activations, there was a positive
correlation between the magnitude of downregulation (change
of sum of squares between the sham and ATD conditions) and
the severity of RSRBs as detected by the ADI-R. This indicated
that subjects with the more severe RSRBs showed the greatest
downregulation by serotonin depletion. We expected that for
the thalamus there would be a negative correlation between
magnitude of upregulation and the severity of RSRBs this time
detected by the ADOS. However, we found the reverse, i.e. for
the thalamic activations the correlation indicated that subjects
with the more severe RSRBs showed the least upregulation
(Fig. 3C). This may reflect difficulties of measuring RSRBs in
adult subjects with the ADOS (Lord et al., 2012) and our small
sample size.
These findings offer the first direct evidence that inhibitory brain
dysfunctions may underpin RSRB in autism, and that these may be
linked to differences in serotonin. It is unlikely that the differential
modulation of inhibitory activations by ATD can be explained by
potential confounds such as differences in task performance or in
Figure 2 Interaction of 5-HT status (sham, ATD) by group (Control, Autism) for the No-Go versus oddball contrast. (A) Locations of
BOLD signals for interaction ANOVA. Numeric label = z Talairach coordinate. (B) Box plots of mean BOLD signal extracted from each
interaction cluster. Right hemisphere of brain is on the right side of the image. 5-HT = serotonin. *Indicates there is no main effect of 5-HT
status from repeated measure ANOVA. BA = Brodmann area; SSQ = sum of squares.
Table 2 Anatomical location and statistics for BOLD activation for No-Go versus oddball interaction ANOVA
Interaction effects ANOVA Pair-wise effects t-test
Main effects of group Main effects of TRP status

















Region x y z BA Size Sig P Sig P Sig P Sig P Sig P Sig P Sig P Sig P Sig P
Right inferior
frontal cortex
43 33 9 46 209 0.01 0.003 0.03 0.002 0.002
Left thalamus 18 26 4 321 0.001 0.007 0.04 0.001 0.004
Right caudate 7 22 4 87 0.04 0.02 0.006 0.001 0.2*
Right
cerebellum
7 82 24 197 0.01 0.003 0.02 0.0001 0.04
x, y, z = Talairach coordinates; BA = Broadmann area; TRP = tryptophan; Sig = statistical significance; CON = control.
*Did not reach between drink statistical significance.
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plasma tryptophan levels—as depletion had no differential group
effect on task performance or lowering blood tryptophan concen-
tration. The fact that ATD has no effect on performance but sig-
nificantly modulated brain activations in both groups is in line with
previous findings that depletion has a stronger effect on brain
function than behaviour (Rubia et al., 2005; Lamar et al., 2009;
Daly et al., 2010). The detection of behavioural differences may
require more power than our subject number allows (Thirion et al.,
Figure 4 Correlations of No-Go versus oddball contrast BOLD response and the restricted, stereotyped and repetitive behaviours in
autism. These scatter plots depict the BOLD signal plotted against the RSRB scores. (A) Under placebo sham 5-HT condition, No-Go versus
oddball inhibition task with the RSRB from (i) the Autism Diagnostic Interview-Revised (ADI-R); and (ii) the Autism Diagnostic Observation
Schedule (ADOS). (B) Under depletion ATD 5-HT condition, No-Go versus oddball inhibition task with the RSRB scores from (i) the ADI-R;
and (ii) the ADOS. (C) Change in SSQs (sham-ATD) from interaction analysis with the RSRB from (i) the ADI-R; and (ii) the ADOS. Right
hemisphere of brain is on the right side of the image. *Correlation did not survive removal of outliers.
Figure 3 Brain activation maps showing abnormally activated inhibition regions in ASD that were ‘normalized’ by ATD. Location of BOLD
signal changes between groups. Blue indicates controls4ASD; red indicates controls5ASD. Numeric label = z Talairach coordinate. Right
hemisphere of brain is on the right side of the image.
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2007) or alternatively motor inhibition tasks may not be impaired
in subjects with autism (Hill, 2004).
The findings that abnormal brain activation in people with
autism during inhibition was shifted towards control levels by
depletion, and even ‘normalized’ in these regions, may be of
clinical relevance as the amount of modulation by ATD, within
frontal, thalamic and striatal regions, was correlated with the
severity of (respectively) past and current RSRB in autistic individ-
uals. Treatment studies using serotonin agonists in ASD (selective
serotonin re-uptake inhibitors; SSRIs) have reported mixed results
with fluoxetine showing improvements of repetitive behaviours in
adults (Hollander et al., 2012), whereas citalopram (King et al.,
2009) had no effect in children. The reasons for these differing
outcomes are unclear. However, our results suggest another
potential approach—reducing synaptic serotonin using selective
serotonin reuptake enhancers (SSRE). Alternatively, it may be
that individualized medicine approaches can be developed to iden-
tify those adults with ASD whose brain function responds to ser-
otonergic modulation—and to target those individuals with
specifically tailored treatments. It has, however, been reported
(McEwen et al., 2009) that the SSRE tianeptine’s mechanism of
action also involves modulation of glutamate, an additional neuro-
transmitter associated with ASD (Coghlan et al., 2012). Hence it
will be important to further understand both serotonin’s primary
and secondary (downstream) effects. Alternate methods of redu-
cing synaptic serotonin with receptor binding drugs such as risper-
idone may also offer targeted treatments.
Our results also add to existing evidence that serotonin may
play a key role in the pathophysiology of autism. The brain
areas that we found to be differentially modulated by ATD form
part of a fronto-striato-thalamo-cerebellar network of inhibitory
control that develops progressively with age (Rubia et al.,
2007), and has intermediate-to-high levels of serotonin receptors
and transporters (Pazos et al., 1987; Varnäs et al., 2004) in
healthy populations. Further, it has previously been reported by
ourselves and others that in these regions, subjects with ASD have
significant differences from controls in serotonin synthesis
(Chugani et al., 1997), transporters (Nakamura et al., 2010) and
2A receptors (Murphy et al., 2006). Also, our finding that thalamic
modulation by ATD is correlated with severity of RSRB in autism
parallels findings by others of a correlation between repetitive be-
haviours and thalamic serotonin transporter binding (Nakamura
et al., 2010). Finally, our data exploring distinct modulatory effects
of serotonin in subjects with autism (occurring within inhibition
networks), complement our previous findings of serotonergic
effects in areas of emotion processing networks during perception
of fearful and sad faces (Daly et al., 2012). Both networks are
selectively modulated by serotonin and seem to be crucial to the
social difficulties and restricted behaviours associated with autism.
Nevertheless this is an observational and not a longitudinal
study. Also the brain regions we found to be functionally different
have previously been reported to have significant developmental
abnormalities in anatomy, neuronal metabolism and integrity
(Otsuka et al., 1999; Abell et al., 2000; McAlonan et al., 2002;
Friedman et al., 2003). Hence, it is unknown if the difference we
found in brain function between autistic individual and controls,
and/or their differential modulation by tryptophan depletion, are
primary or secondary to differences in brain maturation or (most
likely) a complicated mixture of both. For example, in addition to
its role as a neurotransmitter, serotonin also acts as a trophic, or
differentiation, factor in the human brain (Whitaker-Azmitia,
2001). Given that ASD is a neurodevelopmental disorder, the
region-specific differences in brain activity we observed during
successful response inhibition (with and without ATD) may also
be influenced by disrupted trophic effects of serotonin. Hence,
further studies are required to determine the extent to which
differences in the neurobiology of inhibitory control in ASD are
primarily determined by acute alterations in serotonin tone (i.e.
neurotransmission activity), or by differences in brain maturation
which may be secondary to altered trophic effects of serotonin.
There are some behavioural studies of inhibition that conclude
that serotonin may not modulate response inhibition (Clark et al.,
2005; Chamberlain et al., 2006; Crockett et al., 2009). However,
these data resulted from investigations of Stop-Signal Inhibition
tasks not from the Go/No-Go task that we used. Other data
posit that these two tasks are differentially modulated by serotonin
(Eagle et al., 2008). The authors differentiate the two response-
inhibition tasks into an ‘action restraint’ Go/No-Go task (modu-
lated by serotonin) and an ‘action cancellation’ Stop-Signal task
(not modulated by serotonin). Although our study did not find
behavioural group aberrations in task performance, we believe
this was due to our sample size not being sufficient to find any
differences. The sample size was, however, large enough for
detection of significant brain activation differences, probably
helped by the use of non-parametric statistics, cluster-level thresh-
olding and mixed effects testing of the functional MRI data.
A further limitation to our study is the absence of blood sero-
tonin measurement to screen subjects for hyperserotonaemia.
Additionally, a better indirect indicator of brain serotonin synthesis
is the ratio of tryptophan to the other large neutral amino acids in
the plasma (Fernstrom, 1983). Our data on the plasma levels of
tryptophan suggest that under the sham condition there may be a
certain degree of ‘loading’ tryptophan (Table 1); however, this is
unlikely to have an effect on serotonin loading because the ratio
of tryptophan to other amino acids typically show minimal
increase during sham. Unfortunately, we lack requisite data to
report ratio measures in our sample; previous studies provide clari-
fication of the sham plasma data (Sambeth et al., 2007). While
the focus of our study was on RSRBs as weak executive function-
ing of inhibition in autism, obsessive-compulsive disorder symp-
tomatology, with an enhanced impulse not to inhibit, might also
need to be considered. The ASD group did have higher scores on
the Obsessive-Compulsive Inventory-Revised and Beck Anxiety
Inventory (although no one had received a clinical obsessive-
compulsive disorder diagnosis), but we do not have a behavioural
measure to disentangle how our subjects experience their RSRBs
(i.e. ego-dystonic, ego-syntonic or neutral). Last, we are unable to
generalize our findings in normal intelligence adults to other ASD
groups (e.g. those with intellectual disabilities or children).
However, depletion studies in these groups have significant ethical
considerations, and a necessary first step is to demonstrate differ-
ences in people who are able to give informed consent for
themselves.
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In summary, in people with autism, brain activation differences
of inhibitory control regions are differentially modulated by sero-
tonin, and this may partially underpin some restricted, stereo-
typed, and repetitive symptoms.
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